DDInter1763 DDInter1825
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Temsirolimus {u} (Compound) upregulates {v} (Gene) IL13RA1
IL13RA1 {u} (Gene) is upregulated by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Temsirolimus {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Temsirolimus {u} (Compound) upregulates {v} (Gene) IL13RA1
IL13RA1 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Temsirolimus {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tofacitinib
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Tofacitinib
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Temsirolimus (Compound) upregulates IL13RA1 (Gene) and IL13RA1 (Gene) is upregulated by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Temsirolimus (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Temsirolimus (Compound) upregulates IL13RA1 (Gene) and IL13RA1 (Gene) is upregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Temsirolimus (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib